For research use only
| Cat No. | ABC-TC0483 |
| Product Type | Human Leukemia Cell Lines |
| Cell Type | Lymphoblast |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Leukemia |
| Product Code | JVM 13; JVM13 |
This cell line was derived from the peripheral blood of a human Caucasian male patient with prolymphocytic leukaemia.
JVM‑13 is a human lymphoblastoid cell line derived from peripheral blood of a Caucasian male patient with B‑prolymphocytic leukemia, originally established by Epstein‑Barr virus (EBV) transformation in the presence of phorbol ester TPA, and is part of leukemia/lymphoma cell panels with documented karyotypic abnormalities and immunophenotype consistent with leukemic B‑cell origin. The cells grow in suspension with lymphoblast morphology and express B‑cell markers such as CD19 and CD20, reflecting their leukemic phenotype. JVM‑13 has been included in chronic B‑cell leukemia studies with confirmed Ig gene rearrangements indicating clonal leukemic origin. Evidence for specific in vivo metastatic behavior is not broadly defined. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV‑1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | JVM 13; JVM13 |
| Species | Human |
| Cat.No | ABC-TC0483 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
JVM‑13 is used as an in vitro model of human B‑cell prolymphocytic leukemia for studies of leukemic B‑cell proliferation, immunophenotype characterization, and intracellular signaling pathways. It is applied in investigations of EBV‑associated transformation mechanisms and clonal Ig gene patterns, as well as in drug screening assays to evaluate antiproliferative compounds and immune‑modulating agents relevant to B‑cell leukemia research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
